Related Experiment Video

Updated: May 17, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Erlotinib and gefitinib for elderly patients with advanced non-small-cell lung cancer

Antonio Passaro, Daniele Alesini, Alessia Pochesci

  • 1Division of Medical Oncology, Sapienza - University of Rome, Viale Regina Elena, 324 - 00161, Rome, Italy. a-passaro@hotmail.it.

Anti-Cancer Agents in Medicinal Chemistry
|November 13, 2012
PubMed

Insights

Erlotinib and gefitinib are effective treatments for elderly patients with advanced non-small-cell lung cancer (NSCLC). These epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors offer valid therapeutic options for this patient group.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Epidermal growth factor receptor (EGFR) is overexpressed in non-small-cell lung cancer (NSCLC), driving tumor progression.
  • Erlotinib and gefitinib are EGFR tyrosine kinase inhibitors (TKIs) targeting key cellular processes.

Purpose of the Study:

  • To review the efficacy and role of erlotinib and gefitinib in elderly patients with advanced NSCLC.
  • To analyze randomized and non-randomized clinical trials for therapeutic options in this demographic.

Main Methods:

  • Systematic review of clinical trials.
  • Analysis of randomized and non-randomized studies on erlotinib and gefitinib in elderly NSCLC patients.

Main Results:

  • Erlotinib and gefitinib are approved for NSCLC treatment in various lines of therapy.
  • These TKIs show potential as valid therapeutic options for elderly patients with NSCLC, considering their comorbidities and prognosis.

Conclusions:

  • Erlotinib and gefitinib represent important therapeutic options for elderly patients with advanced NSCLC.
  • Further analysis supports their consideration in managing this patient population.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...